# Cosimo Bruni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8528102/publications.pdf

Version: 2024-02-01

| 144 | 2,495 | 236925 | 265206 |
|---|---|---|---|
| papers | citations | 25 | 42 |
| | | h-index | g-index |

| 144 | 144 | 144 | 2834 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83. | 3.9 | 182 |
| 2 | Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093. | 0.9 | 168 |
| 3 | Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 390-395. | 0.9 | 146 |
| 4 | Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782. | 3.8 | 91 |
| 5 | Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. Frontiers in Immunology, 2018, 9, 2045. | 4.8 | 67 |
| 6 | Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120. | 1.7 | 62 |
| 7 | Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Annals of the Rheumatic Diseases, 2015, 74, 124-128. | 0.9 | 60 |
| 8 | Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology, 2015, 54, 72-76. | 1.9 | 57 |
| 9 | The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609. | 1.9 | 53 |
| 10 | Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726. | 0.9 | 51 |
| 11 | Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clinical Rheumatology, 2012, 31, 1723-1725. | 2.2 | 50 |
| 12 | Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. Chest, 2020, 158, 1515-1525. | 0.8 | 50 |
| 13 | Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology, 2020, 59, 1938-1948. | 1.9 | 42 |
| 14 | Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatology, The, 2021, 3, e834-e843. | 3.9 | 42 |
| 15 | Increased plasma levels of the VEGF<sub>165</sub>b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 1425-1427. | 0.9 | 39 |
| 16 | Very earlyversusearlydisease: the evolving definition of the â€˜many facesâ€™ of systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 319-321. | 0.9 | 37 |
| 17 | Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology, 2016, 55, 1610-1614. | 1.9 | 35 |
| 18 | Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101668. | 3.3 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The need for a holistic approach for SSc-ILD â€“ achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197. | 3.6 | 33 |
| 20 | Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Seminars in Arthritis and Rheumatism, 2020, 50, 1489-1493. | 3.4 | 33 |
| 21 | Kidney involvement in systemic sclerosis: From pathogenesis to treatment. Journal of Scleroderma and Related Disorders, 2018, 3, 43-52. | 1.7 | 32 |
| 22 | Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. Journal of Rheumatology, 2020, 47, 881-887. | 2.0 | 32 |
| 23 | Early Detection of Cardiac Involvement inÂSystemic Sclerosis. JACC: Cardiovascular Imaging, 2019, 12, 927-928. | 5.3 | 30 |
| 24 | Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Review of Clinical Immunology, 2017, 13, 469-482. | 3.0 | 29 |
| 25 | Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. European Journal of Internal Medicine, 2020, 78, 17-25. | 2.2 | 29 |
| 26 | The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clinical Rheumatology, 2020, 39, 2043-2047. | 2.2 | 27 |
| 27 | Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 221. | 3.5 | 26 |
| 28 | Proangiogenic effects of soluble Î±-Klotho on systemic sclerosis dermal microvascular endothelial cells. Arthritis Research and Therapy, 2017, 19, 27. | 3.5 | 26 |
| 29 | Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. Frontiers in Immunology, 2021, 12, 653950. | 4.8 | 26 |
| 30 | One year in review 2016: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 161-71. | 0.8 | 26 |
| 31 | Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 1190-1197. | 2.0 | 25 |
| 32 | Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32. | 1.7 | 25 |
| 33 | Combination therapy with Bosentan and Sildenafil improves Raynaudâ€™s phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clinical Rheumatology, 2016, 35, 127-132. | 2.2 | 24 |
| 34 | The â€œmythâ€•of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?. Arthritis Research and Therapy, 2017, 19, 162. | 3.5 | 24 |
| 35 | Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clinical and Experimental Medicine, 2019, 19, 357-366. | 3.6 | 23 |
| 36 | One year in review 2015: systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2015, 33, 414-25. | 0.8 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The clinical relevance of sexual dysfunction in systemic sclerosis. Autoimmunity Reviews, 2015, 14, 1111-1115. | 5.8 | 22 |
| 38 | Recent advances steer the future of systemic sclerosis toward precision medicine. Clinical Rheumatology, 2020, 39, 1-4. | 2.2 | 21 |
| 39 | Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology, 2020, 59, 3731-3736. | 1.9 | 21 |
| 40 | Monitoring the microcirculation in the diagnosis and followâ€up of systemic sclerosis patients: Focus on pulmonary and peripheral vascular manifestations. Microcirculation, 2020, 27, e12647. | 1.8 | 21 |
| 41 | The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096403. | 2.7 | 21 |
| 42 | Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clinical Rheumatology, 2021, 40, 85-91. | 2.2 | 20 |
| 43 | The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement. Journal of Scleroderma and Related Disorders, 2021, 6, 123-132. | 1.7 | 20 |
| 44 | The emerging role of lung ultrasound in COVID-19 pneumonia. European Journal of Rheumatology, 2020, 7, S129-S133. | 0.6 | 20 |
| 45 | Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clinical Rheumatology, 2020, 39, 27-36. | 2.2 | 18 |
| 46 | Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. Joint Bone Spine, 2017, 84, 747-748. | 1.6 | 17 |
| 47 | Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. Rheumatology, 2017, 56, 317-318. | 1.9 | 17 |
| 48 | 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Annals of the Rheumatic Diseases, 2019, 78, 577-578. | 0.9 | 17 |
| 49 | Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. Annals of the Rheumatic Diseases, 2020, 79, 1210-1217. | 0.9 | 17 |
| 50 | COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. Journal of Scleroderma and Related Disorders, 2021, 6, 58-65. | 1.7 | 17 |
| 51 | The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. Pharmaceuticals, 2021, 14, 403. | 3.8 | 17 |
| 52 | Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 603-608. | 2.0 | 16 |
| 53 | Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis. Rheumatology, 2021, 60, 4508-4519. | 1.9 | 16 |
| 54 | Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clinical Rheumatology, 2016, 35, 2841-2845. | 2.2 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The safety of iloprost in systemic sclerosis in a real-life experience. Clinical Rheumatology, 2018, 37, 1249-1255. | 2.2 | 14 |
| 56 | Digital Ulcers in Systemic Sclerosis. Presse Medicale, 2021, 50, 104064. | 1.9 | 14 |
| 57 | Correlation between Potential Risk Factors and Pulmonary Embolism in Sarcoidosis Patients Timely Treated. Journal of Clinical Medicine, 2021, 10, 2462. | 2.4 | 14 |
| 58 | Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. Clinical Rheumatology, 2017, 36, 209-212. | 2.2 | 13 |
| 59 | Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease â€" Scleroderma Clinical Trials Consortium. Journal of Rheumatology, 2019, 46, 78-84. | 2.0 | 13 |
| 60 | What Role Does Trabecular Bone Score Play in Chronic Inflammatory Rheumatic Diseases?. Frontiers in Medicine, 2020, 7, 600697. | 2.6 | 13 |
| 61 | The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals, 2021, 14, 154. | 3.8 | 13 |
| 62 | Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma. Seminars in Arthritis and Rheumatism, 2019, 48, 867-873. | 3.4 | 12 |
| 63 | Digital ulcer debridement in systemic sclerosis: a systematic literature review. Clinical Rheumatology, 2020, 39, 805-811. | 2.2 | 12 |
| 64 | Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. Clinical Rheumatology, 2021, 40, 1903-1912. | 2.2 | 12 |
| 65 | The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e149-e159. | 3.9 | 11 |
| 66 | Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. Rheumatology, 2022, 61, SI56-SI64. | 1.9 | 11 |
| 67 | One year in review 2017: systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 3-20. | 0.8 | 11 |
| 68 | Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?. Clinical Rheumatology, 2015, 34, 795-798. | 2.2 | 10 |
| 69 | Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. Rheumatology, 2020, 59, 3645-3656. | 1.9 | 10 |
| 70 | Pulmonary arterial hypertension: guidelines and unmet clinical needs. Reumatismo, 2021, 72, 228-246. | 0.9 | 10 |
| 71 | Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Annals of the Rheumatic Diseases, 2022, 81, 507-515. | 0.9 | 10 |
| 72 | Prediction and primary prevention of major vascular complications in systemic sclerosis. European Journal of Internal Medicine, 2021, 87, 51-58. | 2.2 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmunity Reviews, 2021, 20, 102981. | 5.8 | 9 |
| 74 | The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. Clinical Rheumatology, 2022, 41, 573-579. | 2.2 | 9 |
| 75 | Lung vascular changes as biomarkers of severity in systemic sclerosisâ€“associated interstitial lung disease. Rheumatology, 2023, 62, 696-706. | 1.9 | 9 |
| 76 | Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. Annals of the Rheumatic Diseases, 2019, 78, 575-577. | 0.9 | 8 |
| 77 | Further evidence that chilblains are a cutaneous manifestation of <scp>COVID</scp> â€19 infection. British Journal of Dermatology, 2020, 183, 596-598. | 1.5 | 8 |
| 78 | Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosisâ€“Interstitial Lung Disease: A Systematic Review. Frontiers in Medicine, 2021, 8, 807982. | 2.6 | 8 |
| 79 | Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis. Diagnostics, 2022, 12, 1696. | 2.6 | 8 |
| 80 | Avascular bone necrosis: An underestimated complication of systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, e3-e5. | 3.4 | 7 |
| 81 | The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. European Journal of Internal Medicine, 2019, 70, 43-49. | 2.2 | 7 |
| 82 | Cyclophosphamide: similarities and differences in the treatment of SSc and SLE. Lupus, 2019, 28, 571-574. | 1.6 | 7 |
| 83 | Digital ulcers: should debridement be a standard of care in systemic sclerosis?. Lancet Rheumatology, The, 2020, 2, e302-e307. | 3.9 | 7 |
| 84 | The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 241-246. | 2.0 | 7 |
| 85 | The burning question: To use or not to use cyclophosphamide in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 237-241. | 0.6 | 7 |
| 86 | Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage?. Frontiers in Physiology, 2021, 12, 710298. | 2.8 | 7 |
| 87 | Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnostics, 2021, 11, 2165. | 2.6 | 7 |
| 88 | Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clinical and Experimental Rheumatology, 2015, 33, S148-52. | 0.8 | 7 |
| 89 | Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. Rheumatology, 2019, 59, 580-585. | 1.9 | 6 |
| 90 | Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110140. | 2.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110336. | 2.7 | 6 |
| 92 | Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046. | 1.9 | 6 |
| 93 | Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. Journal of Clinical Medicine, 2020, 9, 1310. | 2.4 | 5 |
| 94 | One year in review 2017: idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2017, 35, 875-884. | 0.8 | 5 |
| 95 | Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 161-168. | 0.8 | 5 |
| 96 | Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis. Medicine (United States), 2019, 98, e16086. | 1.0 | 4 |
| 97 | Oral Lactobacillus Species in Systemic Sclerosis. Microorganisms, 2021, 9, 1298. | 3.6 | 4 |
| 98 | Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient. Reumatismo, 2016, 68, 109-111. | 0.9 | 3 |
| 99 | The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 135-141. | 0.8 | 3 |
| 100 | Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 790-792. | 2.0 | 2 |
| 101 | Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort. Journal of Scleroderma and Related Disorders, 2021, 6, 165-169. | 1.7 | 2 |
| 102 | Response to: â€˜Correspondence on â€˜Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient managementâ€™â€™ by Snarskaya and Vasileva. Annals of the Rheumatic Diseases, 2023, 82, e37-e37. | 0.9 | 2 |
| 103 | Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. Seminars in Arthritis and Rheumatism, 2021, 51, 425-429. | 3.4 | 2 |
| 104 | THU0425â€...18f-fluorodeoxyglucose positron emission tomography/computed tomography and lung involvement in systemic sclerosis. , 2018, , . | | 2 |
| 105 | FRI0372â€...The ducas: proposal for a digital ulcer assessment score in scleroderma. , 2017, , . | | 1 |
| 106 | Ulcer Healing and Prevention in Systemic Sclerosis. , 2019, , 167-171. | | 1 |
| 107 | THU0355â€...PARAMETRIC CARDIAC MAGNETIC RESONANCE IMAGING IDENTIFIES ARRHYTHMOGENIC SUBSTRATES IN SYSTEMIC SCLEROSIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 409.2-409. | 0.9 | 1 |
| 108 | AB0239â€...EFFECTS OF DYSMETABOLISMS AND COMORBIDITIES ON THE EFFICACY, SAFETY AND RETENTION RATE OF BIOLOGICAL DMARDS (bDMARD) IN INFLAMMATORY JOINT DISEASES.. Annals of the Rheumatic Diseases, 2020, 79, 1420.1-1420. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Systemic sclerosis and COVID-19: what's new in the literature. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 157-158. | 0.8 | 1 |
| 110 | SAT0150â€…Soluble FAS/FASL levels in rheumatoid arthritis patients treated with infliximab and adalimumab. Annals of the Rheumatic Diseases, 2013, 71, 522.2-522. | 0.9 | 0 |
| 111 | SAT0034â€…Cardiac involvement in systemic sclerosis: The added value of magnetic resonance imaging. Annals of the Rheumatic Diseases, 2013, 71, 482.2-482. | 0.9 | 0 |
| 112 | AB0466â€…Quantiferon (QFT) identifies latent tuberculosis (LTB) but does not help the evaluation of the efficacy of prophylaxis in inflammatory arthritides. Annals of the Rheumatic Diseases, 2013, 71, 664.6-664. | 0.9 | 0 |
| 113 | AB0230â€…Anorectal involvement in very early systemic sclerosis (SSC). Annals of the Rheumatic Diseases, 2013, 71, 650.13-650. | 0.9 | 0 |
| 114 | AB0231â€…Esophageal involvement in very early systemic sclerosis (SSC). Annals of the Rheumatic Diseases, 2013, 71, 650.14-650. | 0.9 | 0 |
| 115 | AB0643â€…The Î¨-Reuma Project: Role of Early and Recent Life Events on Systemic Sclerosis (SSC) Clinical Presentation and Course. Annals of the Rheumatic Diseases, 2014, 73, 1018.1-1018. | 0.9 | 0 |
| 116 | AB0726â€…Combination Therapy with Bosentan and Sildenafil Improves Nailfold Videocapillaroscopy in Systemic Sclerosis (SSC). Annals of the Rheumatic Diseases, 2015, 74, 1141.1-1141. | 0.9 | 0 |
| 117 | A6.28â€…The role of Plexin-D1/Semaphorin 3E pathway in the dysregulation of vascular tone control in systemic sclerosis (SSc). Annals of the Rheumatic Diseases, 2015, 74, A67.1-A67. | 0.9 | 0 |
| 118 | SAT0229â€…A Novel Serum Test Based Algorithm To Aid in Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Annals of the Rheumatic Diseases, 2016, 75, 751.2-751. | 0.9 | 0 |
| 119 | OP0050â€…Serum Levels of Adipokines in The Categories of Body Mass Index (BMI) in Patients with Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 73.2-73. | 0.9 | 0 |
| 120 | FRI0384â€…A mini-invasive technique for haemodynamic evaluation: new perspectives for pulmonary arterial hypertension (PAH) diagnosis in systemic sclerosis (SSC). , 2017, , . | | 0 |
| 121 | Lâ€™hydroxychloroquine et les atteintes articulaires dans la sclÃ©rodermie systÃ©miqueÂ: rÃ©sultats prÃ©liminaires dâ€™une Ã©tude rÃ©trospective cas-tÃ©moins EUSTAR. Revue Du Rhumatisme (Edition Francaise) 2018, 85, 411-412. | 0.9 | 0 |
| 122 | POS0264â€…THE EMERGING ROLE OF MAGNETIC RESONANCE IMAGING IN INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: EVIDENCE FOR ULTRA SHORT TE AND COMPRESSED SENSING VIBE ACQUISITIONS AS PROMISING TOOLS FOR THE EVALUATION OF PARENCHYMAL ALTERATIONS. Annals of the Rheumatic Diseases, 2021, 80, 355.1-355. | 0.9 | 0 |
| 123 | POS1228â€…THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 897.2-898. | 0.9 | 0 |
| 124 | POS1495-HPRâ€…THE EXPERIENCE OF A RHEUMATOLOGY UNIT DURING THE COVID19 LOCKDOWN: TELEMEDICINE ALLOWS A SAFE FOLLOW UP OF PATIENTS WITH RHEUMATIC DISEASES. Annals of the Rheumatic Diseases, 2021, 80, 1032.1-1032. | 0.9 | 0 |
| 125 | POS0321â€…USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT. Annals of the Rheumatic Diseases, 2021, 80, 387.3-388. | 0.9 | 0 |
| 126 | POS0317â€…THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE. Annals of the Rheumatic Diseases, 2021, 80, 385-386. | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | POS0861â€…EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT. Annals of the Rheumatic Diseases, 2021, 80, 685-686. | 0.9 | 0 |
| 128 | POS0855â€…PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING. Annals of the Rheumatic Diseases, 2021, 80, 681.3-682. | 0.9 | 0 |
| 129 | The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by SjÅ'grenâ€™s syndrome patients. Rheumatology and Immunology Research, 2021, 2, 113-119. | 0.8 | 0 |
| 130 | Hand Function in Scleroderma. , 2019, , 91-107. | | 0 |
| 131 | OP0251â€…THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCORE â€" A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 2020, 79, 158-159. | 0.9 | 0 |
| 132 | AB0281â€…SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.. Annals of the Rheumatic Diseases, 2020, 79, 1439.1-1440. | 0.9 | 0 |
| 133 | AB0556â€…PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR), CONSENSUS-BASED DEFINITION AND PRELIMINARY VALIDATION.. Annals of the Rheumatic Diseases, 2020, 79, 1574.1-1575. | 0.9 | 0 |
| 134 | SAT0308â€…SCREENING TOOLS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC): A SYSTEMATIC LITERATURE REVIEW (SLR).. Annals of the Rheumatic Diseases, 2020, 79, 1099.1-1099. | 0.9 | 0 |
| 135 | THU0360â€…EFFICACY OF A SELF-TREATMENT PROTOCOL FOR FACE AND TEMPOROMANDIBULAR JOINTS REHABILITATION IN SYSTEMIC SCLEROSIS (SSC). Annals of the Rheumatic Diseases, 2020, 79, 411.2-411. | 0.9 | 0 |
| 136 | AB0361â€…EFFICACY AND SAFETY OF BARICITINIB (BARI) IN RHEUMATOID ARTHRITIS(RA): CLINICAL AND ULTRASOUND EVALUATION IN REAL LIFE. Annals of the Rheumatic Diseases, 2020, 79, 1481-1482. | 0.9 | 0 |
| 137 | Digital Ulcers. In Clinical Practice, 2021, , 111-122. | 0.0 | 0 |
| 138 | Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. Rheumatology and Immunology Research, 2020, 1, 39-45. | 0.8 | 0 |
| 139 | Purinergic signaling in systemic sclerosis. Rheumatology, 2021, , . | 1.9 | 0 |
| 140 | Late Gadolinium Enhancement at cardiac magnetic resonance predicts malignant ventricular arrhythmias in systemic sclerosis. European Heart Journal, 2020, 41, . | 2.2 | 0 |
| 141 | The relationship between arrhythmogenicity and novel parametric cardiac magnetic resonance indices in systemic sclerosis patients. European Heart Journal, 2020, 41, . | 2.2 | 0 |
| 142 | Antioxidant agents help primary Raynaud's phenomenon. International Angiology, 2015, 34, 94-5. | 0.9 | 0 |
| 143 | Lung involvement in systemic sclerosis. Handbook of Systemic Autoimmune Diseases, 2022, , 73-103. | 0.1 | 0 |
| 144 | Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. Rheumatology and Immunology Research, 2022, 3, 31-37. | 0.8 | 0 |